A combination of imvotamab and loncastuximab tesirine (CD19-directed ADC approved in r/r LBCL after two or more lines of systemic therapy) demonstrated enhanced cytotoxic effect in preclinical studies (125) and is currently tested in first-in-human clinical trial in patients with r/r NHL (NCT04082936). Here, CD19 is linked to non-Hodgkin lymphoma.